Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04451109 · ClinicalTrials.gov registry record
Dilapan-S®: A Multicenter US E-registry
A clinical trial of Gestational Diabetes and Fetal Growth Retardation, sponsored by Medicem Technology s.r.o..
- Active
- Registry status
- 1,200
- Enrollment target
- 1
- Study location
NCT04451109 is a study of Gestational Diabetes and Fetal Growth Retardation that is active but no longer recruiting, run by Medicem Technology s.r.o.. The registered enrollment target is 1,200 participants, above the 293-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (310% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04451109, a study of Gestational Diabetes and Fetal Growth Retardation, is active but no longer recruiting, sponsored by Medicem Technology s.r.o..
- ACTIVE NOT RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective of this registry is to collect a representative set of real world data on the use of Dilapan-S® for pre-induction cervical ripening in daily clinical practice. Upon completion of the registry, relevant collected data will be analyzed and published.
Conditions Studied
Interventions
- DEVICE Dilapan-S
Study Locations (1)
Texas
- The University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2025-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04451109
The ClinicalTrials.gov registry entry for NCT04451109 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 293-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (310% higher). The listed sponsor is Medicem Technology s.r.o., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Gestational Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Dilapan-S is the first listed.
NCT04451109 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04451109 about?
NCT04451109 is a clinical study titled "Dilapan-S®: A Multicenter US E-registry". Objective of this registry is to collect a representative set of real world data on the use of Dilapan-S® for pre-induction cervical ripening in daily clinical practice. Upon completion of the registry, relevant collected data will be analyzed and published.
What is the current status of trial NCT04451109?
This trial is currently active not recruiting. The enrollment target is 1,200 participants. The study started on 2020-12-01. Estimated completion is 2025-06-30.
What conditions does trial NCT04451109 study?
This clinical trial studies the following conditions: Gestational Diabetes, Fetal Growth Retardation, Premature Rupture of Membrane, Oligohydramnios, Post Term Pregnancy.
What interventions are being tested in trial NCT04451109?
The interventions under investigation include: Dilapan-S (DEVICE).
Who is sponsoring clinical trial NCT04451109?
This trial is sponsored by Medicem Technology s.r.o., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04451109 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gestational Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nutrition Optimization and Community Upliftment for Postpartum Recovery
RECRUITING · NA
-
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
RECRUITING · NA
-
Delivering HOPE (Helping Women Optimize Prenatal Equity)
RECRUITING · NA
-
iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes
RECRUITING · NA
-
Evaluating the Efficacy of GPT-based Nutrition and Diabetic Counseling in Gestational Diabetes Management: A Randomized Controlled Trial (AIM-GDM)
RECRUITING · NA
-
Growth Hormone Resistance of Beta-cells
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.